Study: More flu vaccine benefits people with HIV

Individuals with HIV receive greater protection against the flu when given four times the normal dose of flu vaccine, a new study shows. Protective efficacy of the normal dose in HIV-infected people does not regularly show the 70% to 90% efficacy it does in healthy people. "For every antigen studied, the high-dose formulation resulted in an increased average antibody titer and higher seroconversion and seroprotective rates compared with the standard-dose influenza vaccine," the researchers wrote in the Annals of Internal Medicine. Story

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.